{"product_id":"emergentbiosolutions-business-model-canvas","title":"Emergent BioSolutions Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioSolutions's Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Emergent BioSolutions's success with our comprehensive Business Model Canvas. This detailed analysis breaks down their value proposition, customer segments, and key partnerships, offering a clear view of their operational framework. Ideal for anyone seeking to understand how this biopharmaceutical company thrives in a complex market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions' key partnerships with government agencies are foundational to its business.  These include significant collaborations with the U.S. Department of Health and Human Services (HHS), the Administration for Strategic Preparedness and Response (ASPR), and the Department of Defense (DoD).\u003c\/p\u003e\n\u003cp\u003eThese partnerships translate into substantial long-term contracts for developing and supplying medical countermeasures, vital for national security and public health preparedness. For instance, in 2024, the company continued to receive contract modifications for its critical products, such as vaccines for anthrax and smallpox, underscoring its established role in biodefense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Governments and Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions actively collaborates with international governments and organizations beyond the United States, supplying critical medical countermeasures and bolstering global health preparedness. This strategic engagement allows the company to address widespread health challenges and expand its impact on a global scale.\u003c\/p\u003e\n\u003cp\u003eRecent orders for smallpox and mpox products from non-U.S. customers underscore the significant global dimension of Emergent's partnerships and its role in international public health initiatives. These collaborations are crucial for building a more resilient global health infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions acts as a crucial contract development and manufacturing organization (CDMO) for numerous biopharmaceutical companies. This means they help other drug makers bring their products from the initial research phase all the way to market availability.  In 2023, Emergent continued to offer these vital manufacturing services, supporting partners in producing both the active ingredients and the final dosage forms of their medicines.\u003c\/p\u003e\n\u003cp\u003eThese collaborations are built on Emergent's extensive manufacturing infrastructure and deep scientific knowledge. By leveraging these strengths, Emergent enables its partners to overcome complex production challenges. Despite strategic shifts, these CDMO relationships remain a foundational element of Emergent's operational model, contributing to their revenue and industry presence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions actively partners with research institutions and academic centers to bolster its research and development efforts and foster innovation. These alliances are vital for progressing its pipeline of vaccines and therapeutics.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Emergent continued its engagement with various universities and research bodies, focusing on early-stage research for infectious disease countermeasures. These collaborations are designed to leverage external expertise and cutting-edge scientific discoveries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcademic Partnerships:\u003c\/strong\u003e Collaborations with universities provide access to novel research and specialized scientific talent.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearch Institutions:\u003c\/strong\u003e Working with dedicated research organizations helps validate early-stage drug candidates and technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Advancement:\u003c\/strong\u003e These partnerships are instrumental in developing and advancing Emergent's portfolio of vaccines and therapeutics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLong-Term Growth:\u003c\/strong\u003e The company views these R\u0026amp;D collaborations as a key driver for sustained future growth and market leadership.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions leverages a robust network of commercial distribution partners to ensure its critical products reach those who need them. For its widely recognized product, NARCAN Nasal Spray, the company actively collaborates with major retail pharmacy chains and other established distribution channels. This strategic approach is vital for achieving widespread accessibility to the life-saving medication.\u003c\/p\u003e\n\u003cp\u003eThe company is also focused on developing and enhancing specialized platforms, such as NARCANDirect™. This direct-to-consumer channel aims to streamline the process for individuals and public interest organizations to acquire NARCAN Nasal Spray, further broadening its availability. By prioritizing these partnerships and platforms, Emergent BioSolutions underscores its commitment to making essential medical countermeasures readily obtainable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRetail Pharmacy Networks:\u003c\/strong\u003e Partnerships with major pharmacy chains ensure NARCAN Nasal Spray is available in thousands of locations nationwide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialized Distribution Platforms:\u003c\/strong\u003e Initiatives like NARCANDirect™ expand access beyond traditional retail, catering to direct consumer and public interest needs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWidespread Accessibility Goal:\u003c\/strong\u003e The core objective is to make critical products like NARCAN Nasal Spray as accessible as possible to individuals and communities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Access: Strategic Distribution Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions' key partnerships extend to commercial distribution networks, crucial for product accessibility. Collaborations with retail pharmacy chains ensure widespread availability of products like NARCAN Nasal Spray, a critical component of their public health strategy. The company also cultivates direct-to-consumer channels, such as NARCANDirect™, to enhance reach and streamline acquisition for both individuals and public interest groups.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis Business Model Canvas provides a strategic overview of Emergent BioSolutions, detailing its key customer segments, value propositions, and channels for delivering life-saving medical countermeasures.\u003c\/p\u003e\n\u003cp\u003eIt reflects the company's operational focus on government and public health preparedness, highlighting revenue streams from product sales and development contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eEmergent BioSolutions' Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their complex operations, simplifying understanding for stakeholders and facilitating strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelopment of Medical Countermeasures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions' key activity centers on the research, development, and licensure of medical countermeasures against public health threats. This encompasses a broad range of products targeting biological and chemical agents, alongside emerging infectious diseases.\u003c\/p\u003e\n\u003cp\u003eA significant focus is placed on expanding the utility of existing products, as demonstrated by the recent efforts to broaden the indication for ACAM2000®, their smallpox vaccine, to include mpox prevention. This strategic move addresses a pressing public health need.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to innovation is evident in its pipeline and ongoing development efforts, aiming to provide critical solutions for national and global health security. This includes a strong emphasis on preparedness against a spectrum of biological and chemical threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions operates specialized manufacturing facilities crucial for producing its wide range of products, from vaccines to life-saving treatments.  This core activity ensures the availability of essential medical countermeasures.\u003c\/p\u003e\n\u003cp\u003eThe company is actively optimizing its manufacturing footprint, with a strategic focus on consolidating operations at its Winnipeg, Canada, and Lansing, Michigan facilities. This consolidation aims for greater efficiency and streamlined production.\u003c\/p\u003e\n\u003cp\u003eIn 2024, maintaining efficient and compliant manufacturing processes is paramount for Emergent. This is directly tied to fulfilling critical government contract obligations and meeting ongoing market demand for its products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Contracting and Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions’ key activity in government contracting and supply centers on securing and fulfilling crucial contracts with government bodies. This involves the vital task of providing medical countermeasures for national stockpiles.\u003c\/p\u003e\n\u003cp\u003eA significant portion of this activity includes the continuous negotiation of new agreements and the diligent management of existing long-term contracts. Ensuring the timely delivery of essential products to national strategic reserves is paramount.\u003c\/p\u003e\n\u003cp\u003eThe company’s reliance on government contracts is evident in its financial performance. For instance, Emergent BioSolutions secured over $400 million in orders for its smallpox and mpox products spanning 2024 and 2025, highlighting the substantial revenue generated from these partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions actively commercializes and distributes its specialty products, such as NARCAN® Nasal Spray, directly to civilian markets. This includes targeted marketing campaigns and building robust distribution networks to ensure broad availability of their life-saving medications.\u003c\/p\u003e\n\u003cp\u003eThe company's strategy emphasizes expanding over-the-counter access for critical products. In 2023, Emergent reported net sales of $1.05 billion, with their commercial segment playing a significant role. They have been working to make NARCAN® available in a wide range of retail pharmacies and community settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommercialization Focus:\u003c\/strong\u003e Emergent prioritizes making its specialty products, particularly NARCAN® Nasal Spray, accessible to the general public.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Strategy:\u003c\/strong\u003e Efforts are concentrated on establishing and expanding distribution channels within civilian markets, including retail and community outlets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Expansion:\u003c\/strong\u003e The company is actively working to broaden over-the-counter availability of its critical products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Performance:\u003c\/strong\u003e Emergent's commercial operations contributed to their overall financial results, with significant sales reported in recent periods.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Services (CDMO)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions offers a full spectrum of Contract Development and Manufacturing Organization (CDMO) services. These encompass everything from the initial development stages to the final drug product manufacturing, including fill and finish operations.\u003c\/p\u003e\n\u003cp\u003eDespite a period of strategic repositioning, Emergent remains committed to supporting pharmaceutical and biotechnology clients through its CDMO segment. The company is focused on utilizing its broad range of technology platforms to deliver these essential services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDrug Substance Manufacturing\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDrug Product Manufacturing (Fill\/Finish)\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDevelopment Services\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLeveraging Diverse Technology Platforms\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biodefense and Commercial Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions’ key activities are multifaceted, encompassing the development and manufacturing of medical countermeasures, securing government contracts, and commercializing specialty products. The company also provides comprehensive Contract Development and Manufacturing Organization (CDMO) services.\u003c\/p\u003e\n\u003cp\u003eIn 2024, a significant focus remains on fulfilling government contracts, which are a substantial revenue driver. For instance, over $400 million in orders for smallpox and mpox products were secured for 2024-2025. Simultaneously, efforts are underway to expand the over-the-counter accessibility of products like NARCAN® Nasal Spray, contributing to their commercial segment, which saw net sales of $1.05 billion in 2023.\u003c\/p\u003e\n\u003cp\u003eManufacturing optimization is also a critical activity, with consolidation efforts at facilities in Winnipeg and Lansing aimed at enhancing efficiency and ensuring product availability. The company continues to leverage its diverse technology platforms for its CDMO services, supporting clients from early development through fill and finish operations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2023\/2024 Data Points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and Product Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping medical countermeasures against public health threats, including infectious diseases.\u003c\/td\u003e\n\u003ctd\u003eExpanding ACAM2000® indications to include mpox prevention.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment Contracting \u0026amp; Supply\u003c\/td\u003e\n\u003ctd\u003eSecuring and fulfilling contracts for national stockpiles of medical countermeasures.\u003c\/td\u003e\n\u003ctd\u003eOver $400 million in orders for smallpox\/mpox products (2024-2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization \u0026amp; Distribution\u003c\/td\u003e\n\u003ctd\u003eMarketing and distributing specialty products, like NARCAN®, to civilian markets.\u003c\/td\u003e\n\u003ctd\u003eNet sales of $1.05 billion (2023); expanding over-the-counter access.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Operations\u003c\/td\u003e\n\u003ctd\u003eProducing vaccines and life-saving treatments, optimizing facilities.\u003c\/td\u003e\n\u003ctd\u003eConsolidating operations at Winnipeg and Lansing facilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Services\u003c\/td\u003e\n\u003ctd\u003eProviding end-to-end drug development and manufacturing services.\u003c\/td\u003e\n\u003ctd\u003eLeveraging diverse technology platforms for clients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas for Emergent BioSolutions that you see here is the exact document you will receive upon purchase. This preview offers a genuine glimpse into the comprehensive analysis and strategic framework that will be yours to utilize. You can be confident that the detailed sections and insights presented are representative of the complete, ready-to-use file you will download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611414118777,"sku":"emergentbiosolutions-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/emergentbiosolutions-business-model-canvas.png?v=1754756630","url":"https:\/\/growthsharematrix.com\/products\/emergentbiosolutions-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}